0000899243-22-035474.txt : 20221109
0000899243-22-035474.hdr.sgml : 20221109
20221109205108
ACCESSION NUMBER: 0000899243-22-035474
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221109
FILED AS OF DATE: 20221109
DATE AS OF CHANGE: 20221109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
CENTRAL INDEX KEY: 0001787092
STATE OF INCORPORATION: E9
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41551
FILM NUMBER: 221374575
BUSINESS ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (617) 951-5372
MAIL ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Acrivon Therapeutics, Inc.
CENTRAL INDEX KEY: 0001781174
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 825125532
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 ARSENAL WAY, SUITE 100
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-207-8979
MAIL ADDRESS:
STREET 1: 480 ARSENAL WAY, SUITE 100
CITY: WATERTOWN
STATE: MA
ZIP: 02472
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2022-11-09
0
0001781174
Acrivon Therapeutics, Inc.
ACRV
0001787092
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
C/O WELLINGTON MANAGEMENT COMPANY LLP
280 CONGRESS STREET
BOSTON
MA
02210
0
0
1
0
Series B Preferred Stock
Common Stock
888130
D
Each share of Series B Preferred Stock is convertible into shares of Common Stock, on a 1-for-2.466 basis, into the number of shares of Common Stock shown in column 3 without payment of further consideration at any time at the holder's election and will convert immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person
2022-11-09